Nihon Kohden Corporation, a global leader in precision medical products and services, has acquired Advanced Medical Predictive Devices, Diagnostics and Displays, Inc. (“AMP3D”), owners of a vast library of clinical predictive algorithms and a unique software-as-a-service (SaaS) platform. AMP3D’s CoMET® (Continuous Monitoring of Event Trajectories) decision support software utilizes patients’ continuous monitoring data, vital signs, medical records, and laboratory tests to display the patients’ real-time and continuous risk trajectories. Nihon Kohden Digital Health Solutions, Inc. (“NKDHS”) sees the benefit of this SaaS offering and plans to integrate the software into their healthcare ecosystem. The integration of this technology will allow clinicians to monitor potentially catastrophic events before they even occur and decrease mortality and lengths of stay, resulting in better patient outcomes.
NKDHS expects to strengthen its technical development capabilities by combining its core human-machine interface (HMI) technology with AMP3D’s algorithms and software technology. The combination of the two companies’ technologies fortifies NKDHS’ digital health ecosystem and complements their portfolio, expanding the possibilities of their digital health offerings.
“We’re creating a digital health-focused ecosystem of care,” said Harsh Dharwad, President, and CEO of Nihon Kohden Digital Health Solutions, Inc. “The future of healthcare lies within the utilization of data-driven applications to predict onset clinical conditions; this acquisition makes us pioneers in the transformation of the industry.”
Nihon Kohden exists to empower clinicians with continuous patient data and intelligent devices that accompany patients every step of the way. With the acquisition of AMP3D, the medical equipment manufacturer continues to expand its services and offerings provided to experts in the field to make more informed decisions.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
“We are in the business of empowering our health care providers. This acquisition will allow us to provide clinicians holistic patient context before making predictions on patient health conditions,” said Eiichi (Eddie) Tanaka, Corporate Director, Operating Officer, General Manager US Operations, of Nihon Kohden Corporation. “Our long-term vision, BEACON 2030, is to create a brighter future for the better of all, connecting clinicians with the tools they need to elevate the work they do.”
“We founded AMP3D with the vision of changing the paradigm of patient care from reactive to proactive—so that clinicians might anticipate risks to their patients up to 8 hours before subacute events might otherwise be diagnosed,” said Kevin Passarello, CEO of AMP3D. “Nihon Kohden will enable this new era of predictive monitoring at the bedside, and thereby improve patients’ experience of care, better overall population health, and reduce costs.”
“Potentially catastrophic clinical events have ‘signatures’ of illness in the continuous monitoring data that we have demonstrated in the peer-reviewed literature,” said J. Randall Moorman, M.D., AMP3D’s Chief Medical Officer. “Detecting these signatures adds information to the EHR in early diagnosis. Nihon Kohden’s acquisition of AMP3D will leverage this research with ‘best of breed’ technology and global scale.”
The leader in precision medical products continues to set the bar high in the industry by challenging the standard for patient monitoring everywhere and creating an ecosystem of care that’s always there. As innovation in technology progresses, Nihon Kohden will continue to evolve its advanced products and services for the benefit of all.
Source: Biospace